Financials data is unavailable for this security.
View more
Year on year Sarepta Therapeutics Inc grew revenues 33.26% from 933.01m to 1.24bn while net income improved from a loss of 703.49m to a smaller loss of 535.98m.
Gross margin | 85.92% |
---|---|
Net profit margin | 7.43% |
Operating margin | 4.79% |
Return on assets | 3.63% |
---|---|
Return on equity | 12.27% |
Return on investment | 4.38% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Sarepta Therapeutics Inc fell by 541.79m. Cash Flow from Financing totalled 125.00m or 10.05% of revenues. In addition the company used 500.99m for operations while cash used for investing totalled 165.80m.
Cash flow per share | 1.60 |
---|---|
Price/Cash flow per share | 72.38 |
Book value per share | 12.79 |
---|---|
Tangible book value per share | 12.50 |
More ▼
Balance sheet in USDView more
Current ratio | 3.84 |
---|---|
Quick ratio | 3.03 |
Total debt/total equity | 1.01 |
---|---|
Total debt/total capital | 0.5013 |
More ▼